Aldeyra Therapeutics, Inc. - Common Stock (ALDX)

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhibitor investigated by Aldeyra as a treatment for a variety of diseases, including dry eye disease.

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aldeyra investors under the federal securities laws.

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.

The U.S. FDA rejected Aldeyra’s application for a dry eye drug, citing a “lack of substantial evidence.”

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.” Consistent with prior NDA reviews of reproxalap, no safety or manufacturing concerns were identified.

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ.

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.

SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.

This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.